Neha Jaiswal
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Neha Jaiswal has a total of 24 co-authors. Here are the top co-authors by number of shared publications:
- Bo Xu
Department of Pathology, Roswell Park Comprehensive Cancer Center, Buffalo, New York
34 shared publications - David W. Goodrich
Department of Pharmacology and Therapeutics, Roswell Park Comprehensive Cancer Center, Buffalo, New York
34 shared publications - Eduardo Cortes Gomez
Department of Biostatistics and Bioinformatics, Roswell Park Comprehensive Cancer Center, Buffalo, USA
34 shared publications - Henry W. Long
Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Harvard Medical School, Boston, USA
34 shared publications - Jianmin Wang
Department of Biostatistics and Bioinformatics, Roswell Park Comprehensive Cancer Center, Buffalo, USA
34 shared publications - Jie Wang
Department of Biostatistics and Bioinformatics, Roswell Park Comprehensive Cancer Center, Buffalo, New York
34 shared publications
Latest Publications
- Open Access
- 19 February 2026
- Published by American Association for Cancer Research (AACR)
Figure S1 from EZH2 Suppression Diversifies Prostate Cancer Lineage Variant Evolution and Lacks Efficacy in Inhibiting Disease Progression
Characterization of Ezh2 deficient GEMMs
- 19 February 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S1 from EZH2 Suppression Diversifies Prostate Cancer Lineage Variant Evolution and Lacks Efficacy in Inhibiting Disease Progression
Characterization of Ezh2 deficient GEMMs
- Open Access
- 19 February 2026
- Published by American Association for Cancer Research (AACR)
Figure S7 from EZH2 Suppression Diversifies Prostate Cancer Lineage Variant Evolution and Lacks Efficacy in Inhibiting Disease Progression
AR genome binding patterns and transcriptional effects are altered in Ezh2 deficient PrCa
- 19 February 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S7 from EZH2 Suppression Diversifies Prostate Cancer Lineage Variant Evolution and Lacks Efficacy in Inhibiting Disease Progression
AR genome binding patterns and transcriptional effects are altered in Ezh2 deficient PrCa
- Open Access
- 19 February 2026
- Published by American Association for Cancer Research (AACR)
Table S5 from EZH2 Suppression Diversifies Prostate Cancer Lineage Variant Evolution and Lacks Efficacy in Inhibiting Disease Progression
Genes whose expression is correlated with cancer plasticity
- 19 February 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S5 from EZH2 Suppression Diversifies Prostate Cancer Lineage Variant Evolution and Lacks Efficacy in Inhibiting Disease Progression
Genes whose expression is correlated with cancer plasticity
- Open Access
- 19 February 2026
- Published by American Association for Cancer Research (AACR)
Figure S4 from EZH2 Suppression Diversifies Prostate Cancer Lineage Variant Evolution and Lacks Efficacy in Inhibiting Disease Progression
Phenotype of PrCa lineage variants developing in mice
- 19 February 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S4 from EZH2 Suppression Diversifies Prostate Cancer Lineage Variant Evolution and Lacks Efficacy in Inhibiting Disease Progression
Phenotype of PrCa lineage variants developing in mice
- Open Access
- 19 February 2026
- Published by American Association for Cancer Research (AACR)
Figure S6 from EZH2 Suppression Diversifies Prostate Cancer Lineage Variant Evolution and Lacks Efficacy in Inhibiting Disease Progression
Chromatin remodeling in PrCa lineage variants
- 19 February 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S6 from EZH2 Suppression Diversifies Prostate Cancer Lineage Variant Evolution and Lacks Efficacy in Inhibiting Disease Progression
Chromatin remodeling in PrCa lineage variants
- Open Access
- 19 February 2026
- Published by American Association for Cancer Research (AACR)
Table S1 from EZH2 Suppression Diversifies Prostate Cancer Lineage Variant Evolution and Lacks Efficacy in Inhibiting Disease Progression
PCR primers used in the experiments described
- 19 February 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S1 from EZH2 Suppression Diversifies Prostate Cancer Lineage Variant Evolution and Lacks Efficacy in Inhibiting Disease Progression
PCR primers used in the experiments described
- Open Access
- 19 February 2026
- Published by American Association for Cancer Research (AACR)
Table S7 from EZH2 Suppression Diversifies Prostate Cancer Lineage Variant Evolution and Lacks Efficacy in Inhibiting Disease Progression
Differentially DNA methylated regions of the genome
- 19 February 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S7 from EZH2 Suppression Diversifies Prostate Cancer Lineage Variant Evolution and Lacks Efficacy in Inhibiting Disease Progression
Differentially DNA methylated regions of the genome
- Open Access
- 19 February 2026
- Published by American Association for Cancer Research (AACR)
Figure S2 from EZH2 Suppression Diversifies Prostate Cancer Lineage Variant Evolution and Lacks Efficacy in Inhibiting Disease Progression
Ezh2 deficiency alters transcriptional reprogramming during PrCa lineage evolution
- 19 February 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S2 from EZH2 Suppression Diversifies Prostate Cancer Lineage Variant Evolution and Lacks Efficacy in Inhibiting Disease Progression
Ezh2 deficiency alters transcriptional reprogramming during PrCa lineage evolution
- Open Access
- 19 February 2026
- Published by American Association for Cancer Research (AACR)
Figure S5 from EZH2 Suppression Diversifies Prostate Cancer Lineage Variant Evolution and Lacks Efficacy in Inhibiting Disease Progression
Ezh2 deficiency alters transcription factor activity and PrCa lineage subtype evolution
- 19 February 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S5 from EZH2 Suppression Diversifies Prostate Cancer Lineage Variant Evolution and Lacks Efficacy in Inhibiting Disease Progression
Ezh2 deficiency alters transcription factor activity and PrCa lineage subtype evolution
- Open Access
- 19 February 2026
- Published by American Association for Cancer Research (AACR)
Figure S3 from EZH2 Suppression Diversifies Prostate Cancer Lineage Variant Evolution and Lacks Efficacy in Inhibiting Disease Progression
Detection of PrCa lineage variants in vivo
- 19 February 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S3 from EZH2 Suppression Diversifies Prostate Cancer Lineage Variant Evolution and Lacks Efficacy in Inhibiting Disease Progression
Detection of PrCa lineage variants in vivo